MRK - Merck and Eisai announce Phase 3 setbacks for lung cancer therapy
2023-09-22 08:32:33 ET
More on Merck
- Merck: Still Fundamentally Undervalued Considering Keytruda's Prospects
- Merck: A Blue-Chip Dividend Stock Worth Buying
- Is Merck's Long-Term Investment Brilliance Unshaken By COVID-19 Drug Sales Slump?
- Merck granted FDA priority review for Keytruda in uterine cancer
- Merck wins FDA priority review for kidney cancer therapy
For further details see:
Merck and Eisai announce Phase 3 setbacks for lung cancer therapy